Loading
A phase 1/2 trial of Epcoritamab, Prednisone, Cyclophosphamide, Doxorubicin, Rituximab and Vincristine in chronic lymphocytic leukaemia, run by Genmab, active and no longer recruiting.
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome is a phase 1/2 interventional study registered as NCT04623541 by Genmab, with 194 participants enrolled, started 2020-11-25 and due to reach its primary completion in 2027-12. Interventions recorded: Epcoritamab, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, Venetoclax, Lenalidomide and Pirtobrutinib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Prednisone, Vincristine, Rituximab, Doxorubicin and the tag pipeline.
Shares Prednisone, Vincristine, Rituximab, Doxorubicin and the tag pipeline.
Shares Prednisone, Vincristine, Rituximab, Doxorubicin and the tag pipeline.
Shares Prednisone, Vincristine, Rituximab, T-cell engagers (bispecific) and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Eli Lilly (incl. Loxo), Rituximab, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Prednisone, Vincristine, Doxorubicin, Cyclophosphamide and the tag pipeline.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Eli Lilly (incl. Loxo), Chronic lymphocytic leukaemia and the tag pipeline.
Shares Prednisone, Vincristine, Rituximab, Doxorubicin and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/